Parnell Pharmaceuticals Holdings Completes Debt Refinancing With Marathon Asset Management

Author's Avatar
Apr 12, 2019
Article's Main Image

SYDNEY, AUSTRALIA / ACCESSWIRE / July 31, 2018 / Parnell Pharmaceuticals Holdings Ltd. (OTC PINK: PARNF) ("Parnell" or the "Company"), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal and human health solutions, today announced it has entered into a credit agreement with affiliated entities of New York-headquartered Marathon Asset Management ("Marathon"). Parnell will use the proceeds from this transaction to refinance its current outstanding debt, pay transaction expenses and provide for working and growth capital.